Dec 3 2021 This Week in Cardiology Dec 3 2021 This Week in Cardiology

The AMAZE trial of left atrial appendage isolation, non-statin oral lipid lowering drugs, EHR alerts, non-MD care, and obesity are the topics John Mandrola, MD, discusses in this week ’s on Medscape
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology Commentary Source Type: news

Related Links:

We studied laboratory parameters of patients with COVID-19 against the background of chronic pathologies (cardiovascular pathologies, obesity, type 2 diabetes melitus, and cardiovascular pathologies with allergy to statins). A decrease in pH and a shift in the electrolyte balance of blood plasma were revealed in all studied groups and were most pronounced in patients with cardiovascular pathologies with allergy to statin. It was found that low pH promotes destruction of lipid components of the erythrocyte membranes in patients with chronic pathologies, which was seen from a decrease in Na+/K+-ATPase activity and significan...
Source: Bulletin of Experimental Biology and Medicine - Category: Biology Source Type: research
Endocr Metab Immune Disord Drug Targets. 2022 Jan 4. doi: 10.2174/1871530322666220104103325. Online ahead of print.ABSTRACTA new coronavirus pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2], has been on the rise. This virus is fatal for broad groups of populations, including elderly, men, and patients with comorbidities among which obesity is a possible risk factor. The pathophysiologic connections between obesity/metainflammation and COVID-19 may be directly related to increasing soluble ACE2 (angiotensin-converting enzyme 2] levels which potentiates the viral entrance into the host cells, ...
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - Category: Endocrinology Authors: Source Type: research
Alzheimers Dement. 2021 Dec;17 Suppl 8:e054527. doi: 10.1002/alz.054527.ABSTRACTBACKGROUND: It is estimated that up to 40% of Alzheimer's Disease and Related Dementias cases can be prevented or delayed by addressing modifiable factors including those that influence vascular risk (hypertension, obesity, smoking, physical activity, diabetes). Prevention may be particularly important in the vascular dementia subtypes. Despite the supporting evidence, the rates of medical therapy to reduce vascular risk are not well described.METHOD: We assessed the utilization of statins, aspirin, and blood pressure (BP) medications in adults...
Source: The Journal of Alzheimers Association - Category: Psychiatry Authors: Source Type: research
CONCLUSION: Existing data indicate a preventing effect of statin therapy on OA progression. However, unless a formal meta-analysis with weight analysis is made, a conclusion cannot be drawn.PMID:34964026 | PMC:PMC8693300 | DOI:10.31138/mjr.32.3.227
Source: Atherosclerosis - Category: Cardiology Authors: Source Type: research
Rev Cardiovasc Med. 2021 Dec 22;22(4):1569-1575. doi: 10.31083/j.rcm2204162.ABSTRACTLipoprotein(a) (Lp(a)) is becoming increasingly important as an independent risk factor for cardiovascular disease. Since no effective therapy currently exists other than lipid apheresis, the recommendation remains to optimally adjust all other cardiovascular risk factors (CVRF). In a Northwest German population study, the frequency of elevated Lp(a) levels and all other CVRF was investigated. The aim was to investigate whether individuals with elevated Lp(a) levels were also more likely to have other CVRFs. To date, 4602 individuals have b...
Source: Reviews in Cardiovascular Medicine - Category: Cardiology Authors: Source Type: research
More News: Cardiology | Cholesterol | Eating Disorders & Weight Management | Heart | Obesity | Podcasts | Statin Therapy